William Shankle
Neurology · Newport Beach, CANPI 1932246584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Lilly USA, LLC at 25.2% of the total. That places this record below the midpoint for neurology clinicians in CA, where the typical reported total is $885.
Across 13 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$79
- Avanir Pharmaceuticals, Inc.$42
- Corium, LLC$31
- Otsuka America Pharmaceutical, Inc.$28
- Grifols USA, LLC$25
- Pfizer$24
- plus $83 from 4 others
Across 43 payments — averaging $25,095 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$853K
- Eisai Inc.$175K
- Genentech, Inc.$51K
- Eli Lilly$75
What the payments were for
- Food & beverage$313100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 3 | $79 |
| Avanir Pharmaceuticals, Inc. | 2 | $42 |
| Corium, LLC | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Grifols USA, LLC | 1 | $25 |
| Pfizer | 1 | $24 |
| Biogen | 1 | $23 |
| Alfasigma USA, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
How this compares
$313 in reported general payments places this provider in the 35th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 736 | $150,902 |
| Memantine Hcl ErMemantine Hcl | 1,142 | $145,610 |
| Repatha SureclickEvolocumab | 51 | $41,830 |
| Dipyridamole | 208 | $16,437 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 163 | $12,872 |
| Galantamine ErGalantamine Hbr | 114 | $12,649 |
| RivastigmineRivastigmine Tartrate | 101 | $7,562 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 82 | $7,331 |
| Praluent PenAlirocumab | 13 | $6,047 |
| Bupropion XlBupropion Hcl | 15 | $4,963 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 32 | $2,298 |
| Memantine Hcl | 60 | $2,167 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 60 | $1,287 |
| Ezetimibe | 48 | $1,211 |
| Ropinirole Hcl | 83 | $1,086 |
Paid to pharmacies, not to this prescriber.
Other neurology in Newport Beach
- Daniel BandariNewport Beach$2.6M
- Christopher O CarrollNewport Beach$761K
- Neal HermanowiczNewport Beach$431K
- Yasir JassamNewport Beach$260K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.